Phase 1 clinical trial of phage-based COVID-19 vaccine - Adaptive Phage Therapeutics
Latest Information Update: 10 Apr 2024
At a glance
- Drugs COVID-19 Vaccine Adaptive Phage Therapeutics (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 18 Mar 2024 According to a BiomX media release, Adaptive Phage Therapeutics has been acquired and merged into BiomX
- 25 Aug 2020 New trial record
- 20 Aug 2020 According to an Adaptive Phage Therapeutics media release, Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus (SARS-CoV-2). The effort will advance and evaluate vaccine candidates in Phase 1 clinical trials.